This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 2/2/90    most recent CIRCHEARTFAILURE.108.807032v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Georgiopoulou, V. V. Articles by Butler, J. Search for Related Content PubMed PubMed Citation Articles by Georgiopoulou, V. V. Articles by Butler, J. Related Collections Other heart failure Other Treatment Related Articles

Original Articles

Digoxin Therapy Does Not Improve Outcomes in Patients With Advanced Heart Failure on Contemporary Medical Therapy

Vasiliki V. Georgiopoulou, MD; Andreas P. Kalogeropoulos, MD; Grigorios Giamouzis, MD, PhD; Syed A. Agha, MD; Mohammad A. Rashad, MD; Sana Waheed, MD; Sonjoy Laskar, MD; Andrew L. Smith, MD and Javed Butler, MD, MPH

From the Center for Heart Failure Therapy, Emory University Hospital, Atlanta, Ga.

Correspondence to Javed Butler, MD, MPH, Emory University Hospital, 1365 Clifton Road, NE, Suite AT430, Atlanta, GA 30322. E-mail javed.butler{at}emory.edu

Received July 14, 2008; accepted January 9, 2009.

Background— The impact of digoxin on outcomes of patients with advanced heart failure (HF) receiving optimal contemporary therapy is not known.

Methods and Results— We retrospectively reviewed data of 455 advanced HF patients referred for transplant evaluation (age, 52±12 years; ejection fraction, 18.3±8%); 227 (49.9%) were on digoxin at baseline. Primary outcome was death (n=101), urgent transplantation (n=14), or ventricular assist device implantation (n=4); secondary outcomes included HF and all-cause hospitalizations. Digoxin use was evaluated (1) in the original cohort; (2) in a propensity score–matched subset (n=322); (3) as a time-dependent covariate; and (4) after adjustment for Seattle Heart Failure Score. Patients were on optimal therapy: angiotensin-II modulation, 92.5%; β-blockers, 91.2%; aldosterone antagonists, 45.6%; and devices, 71.0%. After a median of 27 months, 83 of 277 (36.6%) patients treated with digoxin versus 36 of 228 (15.8%) patients without digoxin met primary outcome (hazard ratio [HR], 2.28; 95% CI, 1.51 to 3.43; P<0.001). This risk persisted in the matched subset (HR, 1.73; 95% CI, 1.09 to 2.75; P=0.021) and with time-varying digoxin use (HR, 2.05; 95% CI, 1.23 to 3.41; P=0.011). Digoxin was associated with higher risk among patients in sinus rhythm compared with atrial fibrillation. Digoxin was not associated with improvement in either all-cause or HF hospitalization rates. These results were similar across sex and race and when adjusted for Seattle Heart Failure Score and renal function.

Conclusion— This study suggests that digoxin therapy may be of no benefit in patients with advanced HF referred for cardiac transplantation who received optimal medical therapy. Treatment with digoxin should be used cautiously in such patients because of risk for adverse outcomes.

Key Words: heart failure • digoxin • outcomes • prognosis • morbidity • mortality

---

 

CLINICAL PERSPECTIVE

Related Articles

Digoxin: Quo Vadis?

John G.F. Cleland and Damien Cullington
Circ Heart Fail 2009 2: 81-85. [Extract] [Full Text] [PDF]

Digoxin Therapy Does Not Improve Outcomes in Patients With Advanced Heart Failure on Contemporary Medical Therapy

Vasiliki V. Georgiopoulou, Andreas P. Kalogeropoulos, Grigorios Giamouzis, Syed A. Agha, Mohammad A. Rashad, Sana Waheed, Sonjoy Laskar, Andrew L. Smith, and Javed Butler
Circ Heart Fail 2009 2: 90-97. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. G.F. Cleland and D. Cullington Digoxin: Quo Vadis? Circ Heart Fail, March 1, 2009; 2(2): 81 - 85. [Full Text] [PDF]